BRUSSELS, March 21 (Reuters) - Europe's top court should

back U.S. gene sequencing company Illumina's ( ILMN ) appeal

against the EU antitrust regulators' review of its $7.1 billion

bid for cancer test maker Grail, an adviser to the

court said on Thursday.

A lower tribunal in 2022 had sided with the European

Commission, prompting Illumina ( ILMN ) to take its case to the

Luxembourg-based Court of Justice of the European Union (CJEU).

CJEU Advocate General Nicholas Emiliou said judges should

set aside the General Court judgment and annul Commission

decisions on referral request.

Judges usually follow such non-binding opinions in the

majority of cases.

The case is C-625/22 P - Grail v Commission and Illumina ( ILMN ).